<DOC>
	<DOCNO>NCT00832624</DOCNO>
	<brief_summary>assess effect treatment Sitagliptin ( MK0431 ) HbA1c ( Hemoglobin A1c ) safety tolerability Sitagliptin .</brief_summary>
	<brief_title>The Effect Sitagliptin Type 2 Diabetes Mellitus With Inadequate Glycemic Control ( MK0431-118 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Patients Who Are 18 Years Of Age With Type 2 Diabetes Mellitus Who Are Either : Not On Antihyperglycemic ( AHa ) Medication ( Off For At Least 2 Months ) Or On A Single AHa</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>